ERBB2 and breast cancer: As previously mentioned, GRP78′s role in drug resistance is not restricted to endocrine therapy and to ER-positive BCs, being involved in resistance to anthracyclines [82,86] and being its expression elevated in different BC subtypes, such as HER2-like [91].